Recommendation for the Future Policy of MAT

RIZA SARASVITA, PHD
HANS DHARMA
INDONESIA

Existing Policies

- Current regulation related to Methadone & Buprenorphine:
 - Drug Law No. 35/2009 regarding Narcotics: methadone is scheduled under # 2, while buprenorphine is # 3
 - Minister of Health Regulation No. 57/2013 regarding National Guideline of Methadone Maintenance Program
 - Minister of Health Regulation related to buprenorphine has not been endorsed yet up to now
- By law, methadone & buprenorphine should be:
 - Available in pharmacy units
 - Prescribed only by trained doctors
 - Dispensed only by pharmacists or assigned pharmacist assistants

Methadone Maintenance Treatment Clinics

- Basis:
 - PHC-based
 - Hospital-based
 - Prison-based
- Run by team, consist of:
 - Doctor
 - Nurse
 - Pharmacist (or the assistant)
 - Psychologist or addiction counselor

Implementation of MMT

- The Clinics must be led by a doctor (trained GP, psychiatrist)
- Pharmacist (or their assistant) dispenses methadone directly to the patient based on doctor's prescription
- Clinics should regularly offer HIV and STI screening and testing, also remind their patients regarding safe sex and safe using practice
 - Hospital-based MMT clinics should provide integrated HIV treatment and care
 - PHC-based MMT clinics should establish referral system for HIV treatment and care

Drop-out patients

- Operational definition
 - Those who do not take methadone for 7 days consecutively and without any explaination/reasoning
- □ Re-entry patients should be re-assessed comprehensively
- □ Study in 2012:
 - Average of drop-out rate for 3 months: 26%
 - Average of drop-out rate for 6 months: 34%
- Predictive factors for treatment retention:
 - Adequate dose
 - THD privileges
 - Clinical experience

Take-home dose policy

- Clinically stable and have been in treatment at least for 3 months
 - □ THD for those who have been in treatment for < 3 months is allowed under very special and limited circumstances
- □ Have regular/daily activities (job, study)
- Being responsible to the home-doses:
 - More preferable w/ family/guardian control
- □ No longer misusing any psychoactive substance → proven by negative drug panel urine test (randomly & regularly checked)

Take-home dose policy

- The doses given should not exceed 3 daily doses, except in special circumstances:
 - Joining training / pilgrimage / competition in places where methadone are not available

Evaluation of MMT Program related to ARV access

- Ever had in ARV: 47.83% → among them, 68.6% actively access ARV
- Core motivator is counselor (OR 3.907 95% CI 1,113 13,708); doctors and/or other health workers do not really motivate them to access ARV
- Patient's uncertainty in adhering ARV regiment was the most significant factor not to access ARV (OR 22,04, 95% CI 1,431 – 339,428)

Evaluation on MMT Program and Its Relation to ARV access (2012)

- > 60% MMT patients are HIV positive
- Ever had in ARV: 47.83% → among them, 68.6% actively access ARV
- Counselors were considered as the main motivator to access ARV
- Patient's uncertainty in ARV regiments was the most significant factor not to access ARV

Recommendations

(source: external review, 2012; coordination meetings, 2013 – 2014)

- Ensure the optimal dose is reached to yield good retention to treatment
- □ Ensure MAT, both methadone and buprenorphine, is affordable
- Increase the number of sites, especially the PHC-based sites > widen the coverage
- Ensure the availability of psychosocial intervention as essential component in providing MAT
- Ensure the clinic's operation hours meet the patients' needs, especially for those who work
- Support prison-based service with continuous technical and operational support

Recommendations (cont

(source: external review, 2012; coordination meetings, 2013 – 2014)

- Establish intersectoral collaboration (with Ministry of Social, National Narcotics Board, Local Government) to get support in:
 - Case management
 - Staff capacity building
 - Good governance service
 - Local government budget to increase service quality / performance
 - Employment opportunity for stable patients

Thank You